Receptor, ErbB-2

Home
About
Help
History (1)
- Receptor, ErbB-2
- See All Pages

"Receptor, ErbB-2" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

A cell surface protein-tyrosine kinase receptor that is overexpressed in a variety of ADENOCARCINOMAS. It has extensive homology to and heterodimerizes with the EGF RECEPTOR, the ERBB-3 RECEPTOR, and the ERBB-4 RECEPTOR. Activation of the erbB-2 receptor occurs through heterodimer formation with a ligand-bound erbB receptor family member.

Descriptor ID	D018719
MeSH Number(s)	D08.811.913.696.620.682.725.400.009.400 D12.776.543.750.630.009.400 D12.776.543.750.750.400.074.400 D12.776.624.664.700.642 D23.050.301.500.600.700 D23.050.705.552.600.550 D23.101.140.642
Concept/Terms	Receptor, ErbB-2 Receptor, ErbB-2 ErbB-2 Receptor Antigens, CD340 CD340 Antigens Proto-Oncogene Proteins c-erbB-2 Proto Oncogene Proteins c erbB 2 p185(c-neu) c-erbB-2 Protein c erbB 2 Protein erbB-2 Proto-Oncogene Protein Proto-Oncogene Protein, erbB-2 erbB 2 Proto Oncogene Protein erbB-2 Receptor Protein-Tyrosine Kinase erbB 2 Receptor Protein Tyrosine Kinase neu Proto-Oncogene Protein Proto-Oncogene Protein, neu neu Proto Oncogene Protein HER-2 Proto-Oncogene Protein HER 2 Proto Oncogene Protein Proto-Oncogene Protein, HER-2 Proto-Oncogene Protein HER-2 Proto Oncogene Protein HER 2 Receptors, erbB-2 erbB-2 Receptors Neu Receptor Receptor, Neu Metastatic Lymph Node Gene 19 Protein Proto-oncogene Protein Neu Neu, Proto-oncogene Protein Proto-oncogene c-ErbB-2 c-ErbB-2, Proto-oncogene Tyrosine Kinase-type Cell Surface Receptor HER2 Tyrosine Kinase type Cell Surface Receptor HER2 p185erbB2 Protein CD340 Antigen Oncogene Protein HER-2 Oncogene Protein HER 2 Proto-Oncogene Protein p185(neu)

Below are MeSH descriptors whose meaning is more general than "Receptor, ErbB-2".

Chemicals and Drugs [D]
Enzymes and Coenzymes [D08]
Enzymes [D08.811]
Transferases [D08.811.913]
Phosphotransferases [D08.811.913.696]
Phosphotransferases (Alcohol Group Acceptor) [D08.811.913.696.620]
Protein Kinases [D08.811.913.696.620.682]
Protein-Tyrosine Kinases [D08.811.913.696.620.682.725]
Receptor Protein-Tyrosine Kinases [D08.811.913.696.620.682.725.400]
ErbB Receptors [D08.811.913.696.620.682.725.400.009]
Receptor, ErbB-2 [D08.811.913.696.620.682.725.400.009.400]
Amino Acids, Peptides, and Proteins [D12]
Proteins [D12.776]
Membrane Proteins [D12.776.543]
Receptors, Cell Surface [D12.776.543.750]
Receptor Protein-Tyrosine Kinases [D12.776.543.750.630]
ErbB Receptors [D12.776.543.750.630.009]
Receptor, ErbB-2 [D12.776.543.750.630.009.400]
Receptors, Peptide [D12.776.543.750.750]
Receptors, Growth Factor [D12.776.543.750.750.400]
ErbB Receptors [D12.776.543.750.750.400.074]
Receptor, ErbB-2 [D12.776.543.750.750.400.074.400]
Neoplasm Proteins [D12.776.624]
Oncogene Proteins [D12.776.624.664]
Proto-Oncogene Proteins [D12.776.624.664.700]
Receptor, ErbB-2 [D12.776.624.664.700.642]
Biological Factors [D23]
Antigens [D23.050]
Antigens, Surface [D23.050.301]
Histocompatibility Antigens [D23.050.301.500]
Minor Histocompatibility Antigens [D23.050.301.500.600]
Receptor, ErbB-2 [D23.050.301.500.600.700]
Isoantigens [D23.050.705]
Histocompatibility Antigens [D23.050.705.552]
Minor Histocompatibility Antigens [D23.050.705.552.600]
Receptor, ErbB-2 [D23.050.705.552.600.550]
Biomarkers [D23.101]
Biomarkers, Tumor [D23.101.140]
Receptor, ErbB-2 [D23.101.140.642]

Below are MeSH descriptors whose meaning is related to "Receptor, ErbB-2".

Below are MeSH descriptors whose meaning is more specific than "Receptor, ErbB-2".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Receptor, ErbB-2" by people in this website by year, and whether "Receptor, ErbB-2" was a major or minor topic of these publications.

Bar chart showing 40 publications over 20 distinct years, with a maximum of 5 publications in 2009 and 2012

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
1995	0	1	1
1996	1	0	1
2000	1	1	2
2004	1	0	1
2006	1	0	1
2007	2	1	3
2008	1	1	2
2009	2	3	5
2010	1	1	2
2011	0	1	1
2012	1	4	5
2013	0	2	2
2014	0	2	2
2015	1	1	2
2017	1	1	2
2019	1	0	1
2020	0	1	1
2021	1	1	2
2022	0	1	1
2024	3	0	3

Below are the most recent publications written about "Receptor, ErbB-2" by people in Profiles.

Avelino ARM, Pulipati S, Jamouss K, Bhardwaj PV. Updates in Treatment of HER2-positive Metastatic Breast Cancer. Curr Treat Options Oncol. 2024 Dec; 25(12):1471-1481.

View in: PubMed
Bhardwaj PV, Abdou Y. Navigating Treatment Pathways in Metastatic Hormone Receptor-Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies. J Clin Oncol. 2024 Dec; 42(34):4012-4017.

View in: PubMed
Khoury K, Meisel JL, Yau C, Rugo HS, Nanda R, Davidian M, Tsiatis B, Chien AJ, Wallace AM, Arora M, Rozenblit M, Hershman DL, Zimmer A, Clark AS, Beckwith H, Elias AD, Stringer-Reasor E, Boughey JC, Nangia C, Vaklavas C, Omene C, Albain KS, Kalinsky KM, Isaacs C, Tseng J, Roussos Torres ET, Thomas B, Thomas A, Sanford A, Balassanian R, Ewing C, Yeung K, Sauder C, Sanft T, Pusztai L, Trivedi MS, Outhaythip A, Li W, Onishi N, Asare AL, Beineke P, Norwood P, Brown-Swigart L, Hirst GL, Matthews JB, Moore B, Fraser Symmans W, Price E, Beedle C, Perlmutter J, Pohlmann P, Shatsky RA, DeMichele A, Yee D, van 't Veer LJ, Hylton NM, Esserman LJ. Datopotamab-deruxtecan in early-stage breast cancer: the sequential multiple assignment randomized I-SPY2.2 phase 2 trial. Nat Med. 2024 Dec; 30(12):3728-3736.

View in: PubMed
Gallo PM, Chain RW, Xu J, Whiteman LM, Palladino A, Caricchio R, Costa-Reis P, Sullivan KE, Gallucci S. EGFR-ErbB2 dual kinase inhibitor lapatinib decreases autoantibody levels and worsens renal disease in Interferon a-accelerated murine lupus. Int Immunopharmacol. 2024 Oct 25; 140:112692.

View in: PubMed
Ling AY, Jreich R, Montez-Rath ME, Meng Z, Kapphahn K, Chandross KJ, Desai M. Transporting observational study results to a target population of interest using inverse odds of participation weighting. PLoS One. 2022; 17(12):e0278842.

View in: PubMed
Murthy SRK, Cheng X, Zhuang T, Ly L, Jones O, Basadonna G, Keidar M, Canady J. BCL2A1 regulates Canady Helios Cold Plasma-induced cell death in triple-negative breast cancer. Sci Rep. 2022 03 08; 12(1):4038.

View in: PubMed
Ersoy E, Cao QJ, Otis CN. HER2 Protein Overexpression and Gene Amplification in Tubo-Ovarian High-grade Serous Carcinomas. Int J Gynecol Pathol. 2022 07 01; 41(4):313-319.

View in: PubMed
Liu B, Singh K, Gong S, Canakci M, Osborne BA, Thayumanavan S. Protein-Antibody Conjugates (PACs): A Plug-and-Play Strategy for Covalent Conjugation and Targeted Intracellular Delivery of Pristine Proteins. Angew Chem Int Ed Engl. 2021 06 01; 60(23):12813-12818.

View in: PubMed
Lenihan D, Carver J, Porter C, Liu JE, Dent S, Thavendiranathan P, Mitchell JD, Nohria A, Fradley MG, Pusic I, Stockerl-Goldstein K, Blaes A, Lyon AR, Ganatra S, L?pez-Fern?ndez T, O'Quinn R, Minotti G, Szmit S, Cardinale D, Alvarez-Cardona J, Curigliano G, Neilan TG, Herrmann J. Cardio-oncology care in the era of the coronavirus disease 2019 (COVID-19) pandemic: An International Cardio-Oncology Society (ICOS) statement. CA Cancer J Clin. 2020 11; 70(6):480-504.

View in: PubMed
Mollica V, Maggio I, Lopez-Beltran A, Montironi R, Cimadamore A, Cheng L, Rizzo A, Giunchi F, Schiavina R, Fiorentino M, Brunocilla E, Massari F. Combination therapy in advanced urothelial cancer: the role of PARP, HER-2 and mTOR inhibitors. Expert Rev Anticancer Ther. 2020 09; 20(9):755-763.

View in: PubMed

People

Explore

Similar Concepts

Top Journals